A number of mice have been cured entirely of lupus by a CAR-T treatment which wipes out the immune system’s B cells by spotting the CD19 protein marker which nearly all B cells carry.
Disruptive science can have a significant impact outside of our own domains of research and into our personal lives. Keeping abreast of these developments can help prepare and inspire.
Researchers at Cold Spring Harbor Laboratory have created a list of genetic “usual suspects” from a computational analysis of 635 datasets across around 27,000 genetic samples.
A second individual has experienced sustained remission from HIV after their treatment ended, scientists from the University of Central London and Imperial College have found.
Biogen has announced it will acquire Nightstar Therapeutics for around $800m, providing the pharma giant with a pipeline of gene therapy candidates for ophthalmology.
Twins born in Australia have become the second-ever-identified pair of “semi-identical” twins, and the first to be detected before they were born. Such cases come about when twins receive 100% identical genes from their mother, but not from their father.
New information from China has suggested that the twins recently created using CRISPR gene-editing technology to make them HIV-resistance could also develop genetically-enhanced brains.
Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have determined a new way to deliver DNA editing tools so that the presence of their proteins in cells is reduced, in what they have called a “hit and run” approach.
Scientists have used synthetic nucleotides to double the traditional number of life’s building blocks to eight.
Roche is set to pay $4.3bn for the acquisition of Spark Therapeutics, a gene therapy company that will put the pharma giant ahead in one of the biggest growing markets around.
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.
Johnson and Johnson has vowed to become the first pharmaceutical giant to add its medicine prices to television adverts, starting in March 2018. The company said it will list not only product price before rebates or discounts, as well as potential out-of-pocket costs which patients will pay.
More errors occur in DNA replication during times of stress when resources are scares, scientists at the University of Toronto have found.